OncoMatch

OncoMatch/Clinical Trials/NCT07068607

Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial

Is NCT07068607 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments for gastritis, indigestion, helicobacter pylori infection, gastric cancer, peptic ulcer.

Phase 4RecruitingYongquan ShiNCT07068607Data as of May 2026

Treatment: Vonoprazan · Tetracycline 500mg tid · Minocycline · Bismuth · Clarithromycin 500 mg · AmoxicillinThis study aims to evaluate the efficacy of vonoprazan combined with different antibiotics in dual therapy for Helicobacter pylori eradication treatment. Newly infected patients were randomly assigned to four groups: amoxicillin dual therapy, tetracycline dual therapy, minocycline dual therapy, and bismuth quadruple therapy. At the follow - up visit in the 6th week, urea breath test, rapid urease test, or Helicobacter pylori fecal antigen test will be conducted to confirm eradication.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: Helicobacter pylori eradication treatment

Patients who have been definitely diagnosed with Hp infection and have received antibiotic eradication treatment

Cannot have received: anti-ulcer drugs (proton pump inhibitor)

Exception: PPI within 2 weeks before the Hp infection test

Patients who have been continuously using anti-ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times a week within 1 month before screening)

Cannot have received: antibiotics

Exception: more than 3 times a week within 1 month before screening

Patients who have been continuously using anti-ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times a week within 1 month before screening)

Cannot have received: bismuth complexes

Exception: more than 3 times a week within 1 month before screening

Patients who have been continuously using anti-ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times a week within 1 month before screening)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify